Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLUESTAR: AZD8205 Monotherapy and Combinations in Advanced Solid Tumors
NCT05123482Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 15
01
Overview
A Phase 2 trial of puxitatug samrotecan in breast cancer, biliary tract carcinoma (BTC), ovarian cancer, endometrial cancer (EC), squamous cell carcinoma of the lung (SCCL), sponsored by AstraZeneca. Started Oct 2021; status: recruiting.
02
Drugs
puxitatug samrotecan
03
Conditions
breast cancerbiliary tract carcinoma (BTC)ovarian cancerendometrial cancer (EC)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05123482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123482.